{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:42:02Z","timestamp":1787060522660,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["AbbVie"],"award-info":[{"award-number":["AbbVie"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06097-1","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:27:50Z","timestamp":1774067270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Remission and treatment persistence during sequential therapy in rheumatoid arthritis: results from the Estonian Biologic Treatment Registry"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4911-0486","authenticated-orcid":false,"given":"Katrin","family":"Ulst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0248-6026","authenticated-orcid":false,"given":"Sigrid","family":"Vorobjov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1864-7186","authenticated-orcid":false,"given":"Karin","family":"Laas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1686-356X","authenticated-orcid":false,"given":"Raili","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"6097_CR1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13075-015-0730-2","volume":"17","author":"IM Markusse","year":"2015","unstructured":"Markusse IM, Dirven L, Gerards AH et al (2015) Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. Arthritis Res Ther 17:232. https:\/\/doi.org\/10.1186\/s13075-015-0730-2","journal-title":"Arthritis Res Ther"},{"key":"6097_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"6097_CR3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 73:924\u2013939. https:\/\/doi.org\/10.1002\/acr.24596","journal-title":"Arthritis Care Res"},{"key":"6097_CR4","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.berh.2024.102017","volume":"39","author":"P Studenic","year":"2025","unstructured":"Studenic P, Meissner Y, Kearsley-Fleet L, De Cock D (2025) Role of rheumatoid arthritis registries worldwide: What have they taught us? Best Pract Res Clin Rheumatol 39:102017. https:\/\/doi.org\/10.1016\/j.berh.2024.102017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"6097_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00296-019-04248-1","volume":"39","author":"DP Misra","year":"2019","unstructured":"Misra DP, Agarwal V (2019) Real-world evidence in rheumatic diseases: relevance and lessons learnt. Rheumatol Int 39:403\u2013416. https:\/\/doi.org\/10.1007\/s00296-019-04248-1","journal-title":"Rheumatol Int"},{"key":"6097_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2147\/CLEP.S99490","volume":"8","author":"EH Ibfelt","year":"2016","unstructured":"Ibfelt EH, Jensen DV, Hetland ML (2016) The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO. Clin Epidemiol 8:737\u2013742. https:\/\/doi.org\/10.2147\/CLEP.S99490","journal-title":"Clin Epidemiol"},{"key":"6097_CR7","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1093\/rheumatology\/kez188","volume":"58","author":"PDH Hamann","year":"2019","unstructured":"Hamann PDH, Pauling JD, McHugh N et al (2019) Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor\u2013treated rheumatoid arthritis patients. Rheumatology 58:2162\u20132169. https:\/\/doi.org\/10.1093\/rheumatology\/kez188","journal-title":"Rheumatology"},{"key":"6097_CR8","doi-asserted-by":"publisher","first-page":"R66","DOI":"10.1186\/ar1933","volume":"8","author":"J Listing","year":"2006","unstructured":"Listing J, Strangfeld A, Rau R et al (2006) Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low \u2013 results from RABBIT, the German biologics register. Arthritis Res Ther 8:R66. https:\/\/doi.org\/10.1186\/ar1933","journal-title":"Arthritis Res Ther"},{"key":"6097_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/rheumatology\/kew467","volume":"56","author":"KJ Aaltonen","year":"2017","unstructured":"Aaltonen KJ, Ylikyl\u00e4 S, Tuulikki Joensuu J et al (2017) Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology (Oxford) 56:725\u2013735. https:\/\/doi.org\/10.1093\/rheumatology\/kew467","journal-title":"Rheumatology (Oxford)"},{"key":"6097_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","volume":"81","author":"G Nagy","year":"2022","unstructured":"Nagy G, Roodenrijs NMT, Welsing PMJ et al (2022) EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 81:20\u201333. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220973","journal-title":"Ann Rheum Dis"},{"key":"6097_CR11","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1093\/rheumatology\/keac190","volume":"61","author":"SS Zhao","year":"2022","unstructured":"Zhao SS, Kearsley-Fleet L, Bosworth A et al (2022) Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis. Rheumatology (Oxford) 61:4678\u20134686. https:\/\/doi.org\/10.1093\/rheumatology\/keac190","journal-title":"Rheumatology (Oxford)"},{"key":"6097_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13075-023-03120-9","volume":"25","author":"DA Pappas","year":"2023","unstructured":"Pappas DA, O\u2019Brien J, Guo L et al (2023) Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry. Arthritis Res Ther 25:166. https:\/\/doi.org\/10.1186\/s13075-023-03120-9","journal-title":"Arthritis Res Ther"},{"key":"6097_CR13","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715","journal-title":"Ann Rheum Dis"},{"key":"6097_CR14","unstructured":"Eesti Haigekassa tervishoiuteenuste loetelu\u2013Riigi Teataja https:\/\/www.riigiteataja.ee\/akt\/128062019011. Accessed 22 Nov 2025"},{"key":"6097_CR15","unstructured":"Kasekamp K, Habicht T, V\u00f5rk A et al (2024) Estonia: Health System Summary, 2024"},{"key":"6097_CR16","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1007\/s10067-025-07636-0","volume":"44","author":"RS Salieva","year":"2025","unstructured":"Salieva RS, Zhumabaeva S, Isakov U et al (2025) The role of sequential biologic therapy in rheumatoid arthritis: a systematic review and meta-analysis of efficacy, safety, and predictive factors. Clin Rheumatol 44:3801\u20133828. https:\/\/doi.org\/10.1007\/s10067-025-07636-0","journal-title":"Clin Rheumatol"},{"key":"6097_CR17","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1093\/rheumatology\/keac048","volume":"61","author":"A Fletcher","year":"2022","unstructured":"Fletcher A, Lassere M, March L et al (2022) Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia. Rheumatology (Oxford) 61:3939\u20133951. https:\/\/doi.org\/10.1093\/rheumatology\/keac048","journal-title":"Rheumatology (Oxford)"},{"key":"6097_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13075-023-03251-z","volume":"26","author":"T Fujii","year":"2024","unstructured":"Fujii T, Murata K, Onizawa H et al (2024) Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort. Arthritis Res Ther 26:16. https:\/\/doi.org\/10.1186\/s13075-023-03251-z","journal-title":"Arthritis Res Ther"},{"key":"6097_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","volume":"43","author":"I Flouri","year":"2014","unstructured":"Flouri I, Markatseli TE, Voulgari PV et al (2014) Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum 43:447\u2013457. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.07.011","journal-title":"Semin Arthritis Rheum"},{"key":"6097_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22788","author":"EG Favalli","year":"2016","unstructured":"Favalli EG, Pregnolato F, Biggioggero M et al (2016) Arthritis Care Res 68:432\u2013439. https:\/\/doi.org\/10.1002\/acr.22788. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry"},{"key":"6097_CR21","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/mr\/roaf007","volume":"35","author":"T Takeuchi","year":"2025","unstructured":"Takeuchi T, Pfeifer C, Zhong Y et al (2025) Real-world treatment persistence in csDMARD-IR and bDMARD-IR patients with rheumatoid arthritis in Japan: A large claims database study. Mod Rheumatol 35:626\u2013636. https:\/\/doi.org\/10.1093\/mr\/roaf007","journal-title":"Mod Rheumatol"},{"key":"6097_CR22","doi-asserted-by":"publisher","unstructured":"Torrente-Segarra V, Huizinga TWJ, Salomon-Escoto K, et al (2025) Biological DMARD survival in rheumatoid arthritis patients in clinical practice: a METEOR registry data analysis. Rheumatol Int 45:190. https:\/\/doi.org\/10.1007\/s00296-025-05945-w","DOI":"10.1007\/s00296-025-05945-w"},{"key":"6097_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00296-025-05859-7","volume":"45","author":"LM Risser","year":"2025","unstructured":"Risser LM, Witte T, Englbrecht M et al (2025) Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis \u2013 a retrospective analysis from the RHADAR database. Rheumatol Int 45:100. https:\/\/doi.org\/10.1007\/s00296-025-05859-7","journal-title":"Rheumatol Int"},{"key":"6097_CR24","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s40744-021-00357-1","volume":"8","author":"EA Holdsworth","year":"2021","unstructured":"Holdsworth EA, Donaghy B, Fox KM et al (2021) Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis. Rheumatol Ther 8:1637\u20131649. https:\/\/doi.org\/10.1007\/s40744-021-00357-1","journal-title":"Rheumatol Ther"},{"key":"6097_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/03009742.2021.2003033","volume":"51","author":"G Carrara","year":"2022","unstructured":"Carrara G, Argnani L, Zanetti A et al (2022) Persistence of bDMARD therapy in Rheumatoid Arthritis after first-line TNF-inhibitor failure: the RECORD study of the Italian Society for Rheumatology. Scand J Rheumatol 51:363\u2013367. https:\/\/doi.org\/10.1080\/03009742.2021.2003033","journal-title":"Scand J Rheumatol"},{"key":"6097_CR26","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.3899\/jrheum.190535","volume":"47","author":"P Youssef","year":"2020","unstructured":"Youssef P, Marcal B, Button P et al (2020) Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset. J Rhuematol 47:1174\u20131181. https:\/\/doi.org\/10.3899\/jrheum.190535","journal-title":"J Rhuematol"},{"key":"6097_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00296-024-05752-9","volume":"45","author":"S Neycheva","year":"2024","unstructured":"Neycheva S, Naseva E, Batalov Z, Karalilova R (2024) Discontinuation of biologic and target-specific therapy in patients with rheumatoid arthritis: a retrospective cohort study. Rheumatol Int 45:6. https:\/\/doi.org\/10.1007\/s00296-024-05752-9","journal-title":"Rheumatol Int"},{"key":"6097_CR28","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/acr2.11629","volume":"5","author":"S Aboulenain","year":"2023","unstructured":"Aboulenain S, Li X, Movahedi M et al (2023) Cardiovascular Risk Factors and the Risk of Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results From the Ontario Best Practices Research Initiative. ACR Open Rheumatol 5:712\u2013717. https:\/\/doi.org\/10.1002\/acr2.11629","journal-title":"ACR Open Rheumatol"},{"key":"6097_CR29","doi-asserted-by":"publisher","first-page":"745601","DOI":"10.3389\/fmed.2021.745601","volume":"8","author":"L Argnani","year":"2021","unstructured":"Argnani L, Zanetti A, Carrara G et al (2021) Rheumatoid Arthritis and Cardiovascular Risk: Retrospective Matched-Cohort Analysis Based on the RECORD Study of the Italian Society for Rheumatology. Front Med (Lausanne) 8:745601. https:\/\/doi.org\/10.3389\/fmed.2021.745601","journal-title":"Front Med (Lausanne)"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06097-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06097-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06097-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:54:53Z","timestamp":1776326093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06097-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6097"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06097-1","relation":{"references":[{"id-type":"doi","id":"10.1002\/acr.22788","asserted-by":"subject"}]},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.. K.U. reports honoraria from AbbVie Inc. and Johnson & Johnson; travel support from Pfizer Inc., AbbVie Inc., and Johnson & Johnson; and participation in industry-sponsored clinical trials supported by AbbVie Inc., Takeda, Alfasigma, Novartis, and Sun Pharma. R.M. reports honoraria from AbbVie, Novartis, Stada, Johnson & Johnson, Pfizer, Amgen, and Sandoz; participation in industry-sponsored clinical trials supported by AbbVie, GSK, Novartis, Dr Reddy\u2019s, Celltrion, Sun Pharma, Eli Lilly, Regeneron, Sandoz, Arxg, Takeda, and Moonlake; and educational support from AbbVie, Novartis, Roche, and Accord. K.L. reports honoraria from AbbVie, Sandoz, Janssen, Novartis, and Berlin-Chemie, and travel support from AbbVie, Novartis, and Janssen. S.V. declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Research Ethics Committee of the National Institute for Health Development, Estonia (Tervise Arengu Instituudi inimuuringute eetikakomitee (TAIEK); Study No. 2396, TAIEK meeting protocol No. 44. Decision No. 1122 issued on October 17, 2022.).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waivered due to the retrospective nature of the study (approved by the IRB).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This manuscript is original and has not been published previously, nor is it under consideration for publication elsewhere, in whole or in part.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"ChatGPT (GPT-5.1, OpenAI) was used between March 2025 and January 2026. Specifically, it was applied to assist with drafting, restructuring, and improving the clarity and flow of text. The authors reviewed and edited all AI-assisted content to ensure accuracy and scientific integrity. No AI was used for data collection, analysis, or interpretation.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}],"article-number":"61"}}